Zacks: Analysts Expect MeiraGTx Holdings PLC (NASDAQ:MGTX) to Announce -$0.60 EPS
Brokerages expect MeiraGTx Holdings PLC (NASDAQ:MGTX) to announce earnings of ($0.60) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for MeiraGTx’s earnings. MeiraGTx reported earnings per share of ($0.59) in the same quarter last year, which would suggest a negative year over year growth rate of 1.7%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that MeiraGTx will report full year earnings of ($2.75) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.45) per share. Zacks’ EPS averages are a mean average based on a survey of research firms that cover MeiraGTx.
MeiraGTx (NASDAQ:MGTX) last released its earnings results on Wednesday, August 7th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.47). The business had revenue of $1.98 million during the quarter.
MGTX traded up $0.03 during trading on Monday, reaching $18.32. The stock had a trading volume of 9,827 shares, compared to its average volume of 121,727. The firm has a market capitalization of $625.67 million, a price-to-earnings ratio of -4.17 and a beta of 2.19. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.12. MeiraGTx has a 1-year low of $8.53 and a 1-year high of $30.23. The stock has a 50 day moving average of $21.37 and a two-hundred day moving average of $21.76.
In related news, Director Life Sciences Maste Perceptive acquired 425,531 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $23.50 per share, for a total transaction of $9,999,978.50. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 17.40% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in MGTX. Bank of Montreal Can acquired a new stake in shares of MeiraGTx during the 2nd quarter valued at $35,000. BNP Paribas Arbitrage SA lifted its holdings in shares of MeiraGTx by 50,220.0% in the first quarter. BNP Paribas Arbitrage SA now owns 2,516 shares of the company’s stock valued at $43,000 after purchasing an additional 2,511 shares in the last quarter. Focused Wealth Management Inc purchased a new stake in shares of MeiraGTx in the second quarter valued at $57,000. Fort Sheridan Advisors LLC purchased a new stake in shares of MeiraGTx in the first quarter valued at $182,000. Finally, Financial Advisory Service Inc. purchased a new stake in shares of MeiraGTx in the second quarter valued at $230,000. Institutional investors own 37.41% of the company’s stock.
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
Further Reading: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.